Serum Institute of India (SII), the globe’s major vaccine producer by volume, which has applied to the DCGI (Drugs Controller General of India) for emergency use authorization (EUA) of its pandemic vaccine, is also near signing a contract with the central administration.
The Pune-based pharma company is expected to ink a supply bond with the central administration, under which the value of the pandemic vaccine may be set at Rs 250 per dosage. While giving confirmation about the same, a source informed “talks for signing a supply contract” have reached the last leg and “could be done soon.”
On Monday, Mr. Adar Poonawalla, Serum Institute’s chief executive officer (CEO) shared the info regarding the same on Monday by making a special tweet. In his tweet, he wrote, “As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorization for the first made-in-India vaccine, [email protected] This will save countless lives, and I thank the Government of India and Sri @narendramodi ji for their invaluable support.”
In the meantime, there is still time prior to the pharma giant can start supplying the pandemic vaccine to the low as well as middle income countries by the way of Gavi, the vaccine coalition via public-private worldwide health partnership.
A source stated that till that time, Serum Institute can supply the vaccine to India and meet the initial phase requirement of the administration.
Up until now, the well-known company has approximately 40 million dosages equipped, but, the demand for the same is huge. The Serum Institute has to make a supply of around 200 million dosages of [email protected] and Novavax vaccine candidate to Bill and Melinda Gates Foundation and Gavi at the price of Rs 250 or $3 per dosage for 2021 to get circulated in the low-and-middle-income countries.
Serum Institute will supply 1 billion dosages to AstraZeneca also, out of which around 50 per cent will be for the Indian zone.
In the meantime, the Centre has specified that it would require around 60 million dosages to immunize 30 million individuals on its priority list that include healthcare and frontline vital services workers like public transport operators, municipality staff etc.